Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-07-11
2002-06-11
Raymond, Richard L. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C540S145000, C514S185000
Reexamination Certificate
active
06403788
ABSTRACT:
BACKGROUND OF THE INVENTION
Molecular oxygen is an essential nutrient for nonfacultative aerobic organisms, including humans. Oxygen, although essential for aerobic metabolism, can be converted to poisonous metabolites, such as superoxide anion and hydrogen peroxide, collectively known as reactive oxygen species. Excessive concentrations of various forms of oxygen and of free radicals can have serious adverse effects on living systems, including the peroxidation of membrane lipids, the hydroxylation of nucleic acid bases, and the oxidation of sulfhydryl groups and other sensitive moieties in proteins. If uncontrolled, mutations and cell death result.
Biological antioxidants include well-defined naturally occurring metalloenzymes, such as superoxide dismutase (SOD), catalase (CAT), and selenium glutathione peroxidase, as well as the enzyme, phospholipid hydroperoxide glutathione peroxidase. A large number of diseases or degenerative processes are related to disorders with metalloenzymes involved in the detoxification of reactive oxygen species derived from dioxygen reduction. The role of these metalloenzymes has been demonstrated with animals under-expressing SOD or CAT enzymes. In addition, the induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase has recently been shown (Estévez et al. (2000), Science, 286:2498-2500).
Obstacles exist for the use of recombinant metalloenzymes in therapy including: solution instability, limited cellular accessibility, immunogenicity, short half-lives, cost of production and proteolytic digestion. These synthetic catalytic scavengers must be stable in physiological conditions and, in particular, the metal should be strictly inserted within the ligand to avoid any demetallation and trapping of the metal ion by serum proteins. These synthetic catalytic scavengers must also be soluble in water at pH 7.0. Avoiding synthetic molecules that lead to DNA cleavage is an additional concern.
Consequently, there is a need for new synthetic transition metal complexes with the ability to catalyze the dismutation of the reactive oxygen species derived from the non-controlled reduction of dioxygen. The need exists for providing non-genotoxic water soluble metallophorphyrin derivatives able to act as SOD and CAT mimics without creating oxidative damage of DNA.
SUMMARY OF THE INVENTION
The present invention relates to compounds which are effective as synthetic catalytic scavengers for reactive oxygen species. The compounds are effective as superoxide dismutase (SOD), and/or catalase (CAT), and/or peroxidase (POD) mimetics which, accordingly, have antioxidant and/or free radical scavenging properties and function in vivo as antioxidants. In particular, the present invention relates to non-genotoxic metalloenzyme mimetics, pharmaceutical formulations containing them, methods for their preparation and the use of such compounds in prophylaxis and therapy for diseases and degenerative processes resulting from reactive oxygen species.
The metallophorphyrin derivatives of this invention can be represented by Structural Formula I:
In a preferred embodiment, Structural Formula I is a complex containing a metal ion, preferably a transition metal such as manganese or iron. In Structural Formula I, R
1
, R
2
, R
3
and R
4
are the same or different and are each a group of the formula:
where L is a linker of about 2 to about 12 atoms in length. The atoms within the linker are carbon atoms optionally interspersed with from 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. Preferably L is a linear C
2
-C
6
alkylene group, more preferably ethylene, X is nitrogen or phosphorus; R
13
, R
14
and R
15
are each, independently, hydrogen, alkyl or arylalkyl; Y- is a monovalent anion; R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
and R
12
are each independently selected from the group consisting of hydrogen, alkyl and halo; and each R
16
independently represents one or more substituents independently selected from the group consisting of hydrogen, hydroxy, halo and alkyl.
Herein, halo is, for example, fluoro, chloro, bromo, iodo; preferably it is fluoro, chloro or bromo.
The counter monovalent anion Y can represent any suitable anion with which the complex of Structural Formula I can be formed. Suitable examples include chloride, hydroxide and acetate, preferably chloride or acetate.
In another embodiment, the invention relates to methods of preparing compounds of Structural Formula I.
In another aspect, the invention provides methods of using the compounds of Structural Formula I for prophylaxis or treatment of a free radical associated disease or condition in a mammal.
In yet another aspect, the invention provides pharmaceutical formulations comprising one or more pharmaceutically acceptable carriers, diluents or excipients and a therapeutically effective amount of compound represented by Structural Formula I.
In yet another embodiment, the invention relates to methods of treating, preventing or arresting free radical associated diseases or conditions comprising administering to an individual in need thereof a therapeutically effective amount of a compound represented by Structural Formula I.
REFERENCES:
patent: 4658023 (1987-04-01), Shudo
patent: 4892941 (1990-01-01), Dolphin et al.
patent: 5077394 (1991-12-01), Dolphin et al.
patent: 5192788 (1993-03-01), Dixon et al.
patent: 5202317 (1993-04-01), Bruice
patent: 5236914 (1993-08-01), Meunier et al.
patent: 5268371 (1993-12-01), Mauclaire et al.
patent: 5284647 (1994-02-01), Niedballa et al.
patent: 5599924 (1997-02-01), Therien et al.
patent: 5674467 (1997-10-01), Maier et al.
patent: 5747026 (1998-05-01), Crapo et al.
patent: 5760216 (1998-06-01), Chorghade et al.
patent: 5994339 (1999-11-01), Crapo et al.
patent: 6127356 (2000-10-01), Crapo et al.
patent: 0 337 598 (1989-10-01), None
patent: WO95/10185 (1995-04-01), None
patent: WO96/09053 (1996-03-01), None
patent: WO96/40223 (1996-12-01), None
patent: WO99/55388 (1999-11-01), None
patent: WO 00/75144 (2000-12-01), None
patent: WO 01/26655 (2001-04-01), None
D. Deniaud et al, New. J. Chem. (1998) 901.*
M. Brockhart et al. Organometallics 11 (1992) 3920-3922.*
S. Melov Ann. NY Acad. Sci. 908 (2000) 219-25 (Medline Abstract).*
F. Müller et al. Eur. J. Clin. Invest. 30 (2000) 905-914.*
Bernadou, J., et al., “Potassium Monopersulfate and a Water-Soluble Manganese Porphyrin Complex, [Mn(TMPyP0] (OAC)5, as an Efficient Reagent for the Oxidative Cleavage of DNA,”Biochemistry28:7268-7275 (1989).
Vialas, C., et al., “Guanine Oxidation in Double-Stranded DNA by Mn-TMPyP/KHSO5, 8-Dihydroxy-7, 8-dihydroguanine Residue as a Key Precursor of Imidazolone and Parabanic Acid Derivatives,”J. Am. Chem. Soc.122:2157-2167 (2000).
Meunier, B., “Metalloporphyrins as Versatile Catalysts for Oxidation Reactions-and Oxidative DNA Cleavage,”Chem. Rev.92:1411-1456 (1992).
Batinic-Haberle, I.B., et al., “Relationship Among Redox Potentials, Proton Dissociation Constants of Pyrrolic Nitrogens, and In Vivo and In Vitro Superoxide Dismutating Activities of Manganese(III) and Iron(III) Water-Soluble Porphyrins,”Inorg. Chem. 38:4011-4022 (1999).
Patel, M., et al., “Metalloporphyrin Class of Therapeutic Catalytic Antioxidants,”TiPS20:359-364 (1999).
Doctrow, S.R., et al., “Salen-Manganese Complexes: Combined Superoxide Dismutase/Catalase Mimics with Broad Pharmacological Efficacy,”Advances in Pharmacology38:247-269 (1997).
Crapo, J., “Role of EC-SOD in Modulating Responses to Cerebral Ischemia Reperfusion (Stroke),”International Society of Antioxidants in Nutrition&Health(2ndInternational Conference)Pasteur Institute, 34-35 (2000).
Song, R., et al., “Anti-HIV Activities of Anionic Metalloporphyrins and Related Compounds”,Antiviral Chemistry and Chemotherapy, 8(2) : 85-97 (1997).
Rocha Gonsalves, A.M.d'A., et al., “Sulphonamide Porphyrins in the Biomimetic Oxidations by H2O2. An Efficient Two-phase System, ”An. Quim. Int. Ed., 92(6) :375-380 (1996).
Cosledan Frédéric
Meunier Bernard
Eukarion, Inc.
Habte Kahsay
Hamilton Brook Smith & Reynolds P.C.
Raymond Richard L.
LandOfFree
Non-genotoxic metalloporphyrins as synthetic catalytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-genotoxic metalloporphyrins as synthetic catalytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-genotoxic metalloporphyrins as synthetic catalytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2962770